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ABSTRACT 
Objective: The objective of this research work was to formulate and evaluate the floating drug delivery system containing Risperidone, to improve 
oral bioavailability by increasing gastric residence time.  
Methods: Total fifteen formulations of Risperidone floating tablets were prepared by direct compression method using different grades of HPMC 
polymers, Gelucire, Polyox and NaHCO3. In vivo radiographic studies were performed in human volunteers by incorporating barium sulphate. 
Results: The prepared tablets were characterized and found to exhibit satisfactory physicochemical characteristics. All the prepared batches 
showed good in vitro buoyancy with low floating lag time. It was observed that the tablets remained buoyant for more than 12h. Optimized 
formulation (F15) consisting of HPMC K100M, WSR 301, Gelucire 50/13 and NaHCO3, followed diffusion controlled zero-order kinetics and non-
fickian transport of the drug. FTIR and DSC studies revealed the absence of any chemical interaction between drug and polymers used. The in vivo 
radiographic studies revealed that the tablets remained in the stomach for 6h in fasting human volunteers. In vivo bioavailability studies performed 
in healthy human volunteers and Tmax, Cmax, AUC was calculated and confirmed significant improvement in bioavailability when compared with 
marketed formulation Respidon 2.  
Conclusion: The data obtained thus suggests that floating delivery system of Risperidone can be successfully designed to give controlled drug 
delivery and improved oral bioavailability.  
Keywords: Risperidone, HPMC, Gelucire, X-ray radiographic studies, In vivo bioavailability studies 




The importance of controlled drug delivery systems that release the 
drug over an extended period of time has long been recognized in 
the pharmaceutical field. Application of such controlled release 
technology to oral drug delivery system, however, has been limited 
because the actual time for effective drug delivery is restricted by 
gastrointestinal transit time [1].  
Bioadhesive systems work by adhering to the gastric epithelial cell 
surface or mucin using bioadhesive polymers [2]. Drugs with short 
half-lives are eliminated quickly. Therefore frequent dosing is 
required to maintain the therapeutic activity. To release the drug in 
a sustained and slow manner, GRDDS formulations are one strategy 
[3]. GRDDS have relative low gastric emptying time (GET) of drugs in 
the human gut, the major site of absorption which averages 2-3 h, 
this low dwell time of drugs in upper regions of GI tract results in 
incomplete drug absorption which leads to reduced efficiency of the 
dosage form [4]. To improve the continuous available of the drug to 
the absorption site hydrophilic polymers are used to make the 
dosage form float in the stomach for the longer duration [5].  
However, the issue in the development of oral controlled release 
dosage forms is to prolong the residence time of dosage forms in the 
stomach or upper gastrointestinal (GI) tract until the drug is 
completely released [6]. Rapid GI transit could result in incomplete 
drug release from the drug delivery device in the absorption zone 
leading to the diminished efficacy of the administered dose [7]. The 
principle of buoyant preparation offers a simple and practical 
approach to achieve increased residence time for the dosage form in 
the stomach and sustained drug release. In the present study HPMC 
K4, HPMC K15 and HPMC K100M, HPMC E15 were used since it is 
reported that it swells to a great extent and forms a stronger gel that 
is less prone to erosion. The rate of drug release from the 
hydrophilic matrix is dependent on various factors such as types of 
polymer, the solubility of drug, polymer content, the particle size of 
drug and polymer as well as types and amount of filler used in the 
formulation [8]. The adjustment of polymer concentration, viscosity 
grade and the addition of different types and levels of excipients to 
the polymer matrix can modify the kinetics of drug release [9]. 
Risperidone, a second-generation antipsychotic drug, is widely used 
in the clinical management of schizophrenia, bipolar and irritability 
disorders. Risperidone lipophilic in nature is rapidly and completely 
absorbed orally and extensively metabolized by cytochrome P450 
2D6 into a major metabolite 9-Hydroxy-risperidone. 9-Hydroxy-
risperidone is pharmacological as much potential as that of the parent 
compound [10]. Risperidone has an elimination half-life of 3 h in 
extensive metabolizers and 17 h in poor and extensive metabolizers 
[11]. Therefore, gastric and intestinal transient times have a significant 
effect on the rate and extent of oral absorption of the drug. As a result, 
variable oral bioavailability may be expected. Investigations were 
performed to see the effect of floating agent content and Risperidone 
content upon the floating lag time of the tablets. The impact of 
formulation variables upon the release rate, mean dissolution time 
and release mechanism was also evaluated with the help of various 
mathematical models. Risperidone has absorption window in upper G. 
I. tract, and due to this often display low bioavailability [12]. The aim 
of the present study was to prepare and characterize sustained release 
floating matrix tablets of Risperidone using Gelucire44/14, WSR 301, 
WSR N10, HPMC K4, HPMC K15 and HPMC K100M, HPMC E15. 
MATERIALS AND METHODS 
Materials 
RESPIDON-2 tablet was purchased from Torrent Pharmaceuticals 
Ltd, Mumbai. Risperidone was generous gift sample from Dr. 
Reddy’s Laboratories Ltd, Hyderabad. Hydroxy propyl methyl 
cellulose K-15M and K-100M were obtained from Rubicon labs, 
Mumbai, India, POLYOX WSR 301 and N10 was obtained from Dow 
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Chemical’s, New York. Gelucire 44/14, Gelucire 50/13 and PVP K 30 
were gifted from MSN Labs Ltd, Hyderabad. All other excipients and 
chemicals used were of analytical grade. 
Methods 
Preparation of risperidone floating tablet 
The tablets were prepared by direct compression method [13]. All 
the ingredients except Risperidone were passed through #85 mesh 
prior to mixing. The ingredients were weighed separately and mixed 
to get a uniform polymer mixture. The drug was then mixed with the 
polymer mixtures were lubricated with magnesium state and talc 
was compressed to obtain tablets. 
Formulation development 
Hydrophilic polymer matrix systems were widely used in oral 
controlled drug delivery because of their flexibility to obtain a 
desirable drug release profile, cost effectiveness, and broad 
regulatory acceptance. 
Present study aims in design of sustained release floating 
formulations of Risperidone using hydrophilic polymers to 
control the drug release and a lipid excipient to decrease the 
gastric irritation and to enhance the penetration of drug 
formulations are developed using Gelucire 44/14, Gelucire 
50/13, WSR 301, WSR N10, HPMC K4, HPMC K15 and HPMC 
K100M, HPMC E15 etc. 
 




























F1 2 20 - - - 30 - 20 - 26 
F2 2 22.5 - - - - 30 25 - 18.5 
F3 2 25 - - - - 25 26 20 - 
F4 2 27.5 - - 13.5 15 - 30 10 - 
F5 2 30 - - - 20 - 36 - 10 
F6 2  20 - - - 30 20 26 - 
F7 2 - 22.5 - - 18.5 - 25 - 30 
F8 2 - 25 - - 30 - 25 - 16 
F9 2 - 27.5 - 20 - - 30 18.5 - 
F10 2 - 30 - 15 16 - 35 - - 
F11 2 -  20 - - 30 30 16 - 
F12 2 -  22.5 - - 25.5 38 10 - 
F13 2 - - 25 - - 15 40 - 16 
F14 2 - - 27.5 12.5 14 - 42 - - 
F15 2 - - 30 - - 11 45 - 10 
NOTE: Each formulation contains 1 % magnesium stearate and 1 % talc. Total tablet weight 100 mg.  
 
Evaluation of floating tablets [14] 
a) Thickness 
The thickness of the prepared tablets was tested using vernier 
calipers. The test was done in triplicate and average was determined. 
b) Hardness 
The hardness of prepared tablets was determined using Monsanto 
hardness tester and measured in terms of kg/cm2. 
c) Weight variation 
The weight variation test was performed as per the I. P. guidelines. 
Twenty randomly taken tablets were weighed together and the 
average weight was determined. Each tablet was then weighed 
individually and deviation from average weight was calculated. 
d) Friability 
A sample of twenty randomly selected tablets were accurately 
weighed and placed in a Roche friabilator. It was operated for 4 min 
at a speed of 25 rpm, and then the tablets were removed, de-dusted 
and reweighed. The percent loss in weight due to abrasion and 
impact was calculated as, 
% Friability= (Loss in weight/Initial weight) x 100. 
e) Drug content 
Ten tablets for each batch was taken and triturated. Powder 
equivalent to 100 mg of drug was weighed and was transferred to 
breaker and 0.1N HCl was added and it was then shaken for 5 min 
and finally 0.1N HCl was added to make the volume up to 100 ml and 
solution was then sonicated for 15 min and filtered through 
Whatman filter paper. Finally, a solution was diluted suitably and 
the absorbance of the resultant solution was measured to determine 
the drug content spectrophotometrically at 241 nm using UV/Visible 
spectrophotometer Shimadzu 1800 against 0.1N HCl blank. 
f) Swelling studies 
The extent of swelling was measured in terms of % of weight 
gained by the tablet. One tablet from each formulation was 
weighed and kept in a petri dish containing 50 ml of 0.1N HCl 
buffer solution. At the end of specified time, intervals tablets were 
withdrawn from petri dish and excess buffer blotted with tissue 
paper and weighed. The % of weight gained by the tablet was 
calculated by using the following formula:  
Swelling Index (%) = Mt-M0/M0 X 100 [15]. 
Buoyancy lag time determination and total floating time 
The in vitro buoyancy was determined by the floating lag time. The 
tablet was placed in a 250 ml beaker containing 0.1N HCl. The time 
required for the tablet to rise to the surface for floating was 
determined as the buoyancy lag time and further total floating time 
of all tablets was determined by visual observation [16]. 
In vitro dissolution studies 
In vitro drug release studies for the prepared immediate release, 
tablets were conducted for a period of 12 h using USP XXIV type-II 
(Paddle) dissolution apparatus at 37±0.5 ˚C at 50 rpm using 900 ml 
of 0.1N HCl as dissolution medium. At a predetermined interval of 
time, 5 ml of sample was withdrawn from the dissolution medium 
and replaced with fresh medium. After filtration and appropriate 
dilution, the samples were analyzed for cumulative percentage drug 
release of Risperidone by UV/Visible spectrophotometer Shimadzu 
1800 at 241 nm. 
Wavelength: 241 nm 
Kinetic modeling of drug release  
To analyze the mechanism of drug release from the tablets the in 
vitro dissolution data was fitted to zero order, first order, Higuchi 
and Korsmeyer-Peppas model.  
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Zero order equation 
This equation describes the systems where the release rate is 
independent of the concentration of the dissolved species. The 
dissolution data are fitted into zero order equation. 
Q=Q˳K˳t, 
Where  
Q=Amount of drug released at time t 
Q˳= Amount of drug release initially 
K˳t =Zero order rate constant 
A graph of concentration vs. time would yield a straight line with a 
slope equal to K˳ and the intercept at the origin of the axes. The zero 
order plot is derived from plotting the cumulative percent drug 
dissolved Vs time. 
First order Equation  
The first order equation describes the release from systems where 
dissolution rate is dependent upon the concentration of the 
dissolving species release behavior  
Generally follows the following first order release equation. 
In M= In M0-K1t 
Where 
M is the amount of drug dissolved at time t, 
M0 is the amount of drug dissolved at t=0 and 
M1 is the first order rate constant. 
A graph of log concentration of drug release Vs time yields line. 
Higuchi Square Root law 
A form of the Higuchi Square Root Law is given by equation 
Q=KS√t 
Where  
Q= Amount of drug dissolved at time t, 
Ks=Higuchi rate constant 
The Higuchi square root law equation describes the release from a 
system where the solid drug is dispersed in an insoluble matrix, and 
the rate of drug release is related to the rate of drug diffusion. 
Korsmeyer and Peppas release model 
The release rate data were fitted to the following equation 
Mt/Mα =K. t  
Where 
Mt/Mα= the fraction of drug released, 
K=the release constant‘t’ is the release time. 
‘n’ is diffusion exponent, if n is equal to 0.89, the release is Zero 
order. If n is equal to 0.45 the release is best explained by Fukien 
diffusion, and if 0.45< n < 0.89 then the release is through 
anomalous diffusion or nonfickian diffusions (Swellable and 
Cylindrical Matrix) 
In this model, a plot of log (Mt/Mα) vs. log time was plotted, and the 
slope was noted to explain release pattern. 
Drug excipient compatibility studies 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra for the pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The IR spectrum of the samples was 
prepared using KBr (spectroscopic grade) disks by means of 
hydraulic pellet press at a pressure of seven to ten tons.  
Differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. Accurately 
weighed samples were placed on the aluminum plate, sealed with 
aluminum lids and heated at a constant rate of 5 °C/min, over a 
temperature range of 0 to 250 °C. 
Stability studies 
The stability studies were carried out as per ICH guidelines. The best 
formulation F15 was subjected to accelerated stability test by 
storing at 40±2 °C/75±5% relative humidity in an accelerated 
stability chamber (Remi, Mumbai). After specified period of time (1, 
2 and 3months) samples were withdrawn and floating lag time, total 
floating time and in vitro dissolution studies were conducted [17]  
Radiographic studies 
The radiographic and In vivo bioavailability study protocol of 
Risperidone floating tablets was approved by the Institutional 
Human Ethics Committee (IHEC), bearing No: IHEC/VGOPC/ 
051/2015, Vaagdevi Group of Pharmacy Colleges, Warangal, India.  
Determination of In vivo gastric residence time 
For this study, the tablets are prepared by replacing half the amount 
of drug with barium sulfate. After overnight fasting, the volunteers 
were fed with a low-calorie food. After half an hour, a barium 
sulfate-labeled tablet was given to every subject with 200 ml of 
water. The volunteers were asked to take 200 ml water after every 
1h. At different time intervals (0.5, 2, 4, and 6 h post administration 
of tablets), the volunteers were exposed to abdominal X-ray imaging 
in standing position. The distance between the source of X-rays and 
the subject was kept constant for all images. Thus, the observation of 
the floating tablet movements could be easily noticed. The mean 
gastric retention period was estimated. 
In vivo bioavailability studies 
In vivo study protocol [18] 
Twelve healthy male subjects with a mean age of 28.83±3.60 y 
(ranging from 24 to 34 y), mean weight 69.33±7.61Kg (ranging from 
61 to 79 Kg) and a mean height of 173.17±10.46 cm (ranging from 
157 to 182 cm) participated in this study. Informed and signed 
consent and approval of the Human Ethical Committee were 
obtained. The volunteers were judged healthy on the basis of their 
previous medical history, physical examination and routine 
laboratory tests. None of the subjects used alcohol or tobacco. All 
subjects were free from drugs 15 d before and during the study. 
They were randomly divided into 2 groups of 6 subjects each. The 
subjects were fasted overnight at least 10h prior to dose. After 
collecting the zero hour blood sample (blank). A high standardized 
fat breakfast approximately 900KCal was given in the morning half-
an-hour before administration. Group A received Formulated 
Risperidone and group B received commercial formulation was 
administered with 200 ml of water. All the subjects were given a 
glass of water for every 2 h (approximately 200 ml). Standardized 
lunch, snacks and dinner were provided to all the subjects 
respectively at 4, 8 and 12h after the administration of formulations. 
Blood samples (2 ml) were collected by the intravenous route using 
heparinized disposable syringes at the following times: 0.5, 1, 1.5, 2, 
2.5, 3, 4, 6, 8, 12, 20 and 24h. The blood samples were collected in 
vacutainers containing EDTA as an anticoagulant and immediately 
centrifuged at 3000rpm for 15 min. The separated plasma samples 
were stored at-200C until analyzed.  
Determination of risperidone in human plasma by HPLC method  
Determination of Risperidone using internal standard 
trihexyphenidyl hydrochloride by high performance liquid 
chromatography with a RP-C18 chromatographic column, 
Phenomenex Kinetex (150 mm × 4.6 mm i. d) and a mobile phase 
consisting of methanol: acetonitrile: 0.05M phosphate buffer (pH 
3.7) (60:30:10, v/v/v) at a flow rate 1.0 ml/min and the wavelength 
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detection was 230 nm. The retention time for Risperidone and 
internal standard trihexyphenidyl hydrochloride was 3.797 min and 
5.389 min respectively [19]. 
Preparation of plasma samples for HPLC analysis  
Human plasma (0.5 ml) was prepared for chromatography by 
precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation, the ethanol was 
transferred into a clean tube. The precipitate was resuspended with 
1 ml of acetonitrile by vortexing for 1 min. After centrifugation 
(5000–6000 rpm for 10 min), the acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature. Samples were reconstituted 
in 200µ1 of 50% of acetonitrile and 50% methanol was injected for 
HPLC analysis.  
Pharmacokinetic analysis 
The pharmacokinetic parameters, peak plasma concentrations (Cmax) 
and time to reach peak concentration (tmax) were directly obtained 
from concentration-time data. In the present study, AUC0-t refers to 
the AUC from 0 to 24h, which was determined by linear trapezoidal 
rule and AUC0-α refers to the AUC from time at zero hours to infinity.  
The AUC0-α was calculated using the formula AUC0-t+[Clast/K] where C 
last is the concentration in µg/ml at the last time point and K is the 
elimination rate constant. 
Various pharmacokinetic parameters like the area under the curve 
[AUC], elimination half-life (t½). The volume of distribution (Vd), 
total clearance (ClT) and mean residence time for each subject using 
a non-compartmental pharmacokinetic program. The 
pharmacokinetic parameters were performed by a non-
compartmental analysis using Win Nonlin 3.3® pharmacokinetic 
software (Pharsight Mountain View, CA USA). All values are 
expressed as the mean±SD. Statistical analysis was performed with 
Graph Pad InStat software (version 3.00, Graph Pad Software, San 
Diego, CA, USA) using one-way analysis of variance (ANOVA) 
followed by Tukey–Kramer multiple comparison test. The difference 
with p<0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Evaluation of physicochemical parameters 
 
 
Fig. 1: Risperidone floating tablets
 
Table 2: Physico-chemical parameters of Risperidone floating tablets 
Formula code Hardness (Kg/cm²) Thickness (mm) (%) Friability Uniformity of Weight (mg) 
F1 2.4±0.12 2.39±0.02 0.55±0.01 95±1.6 
F2 2.6±0.16 2.38±0.01 0.53±0.04 95±1.3 
F3 2.3±0.21 2.38±0.03 0.66±0.02 98±1.7 
F4 2.9±0.14 2.37±0.01 0.67±0.04 95±2.4 
F5 2.8±0.19 2.35±0.01 0.75±0.05 96±2.1 
F6 2.0±0.2 2.36±0.02 0.72±0.02 97±2.2 
F7 2.2±0.8 2.38±0.03 0.70±0.01 96±1.4 
F8 2.7±0.02 2.39±0.03 0.65±0.02 97±1.5 
F9 2.6±0.8 2.39±0.02 0.66±0.01 98±1.0 
F10 2.4±0.1 2.39±0.03 0.57±0.03 96±1.2 
F11 2.5±o,1 2.42±0.04 0.52±0.02 98±1.6 
F12 2.3±o.2 2.46±0.03 0.58±0.06 95±2.0 
F13 2.4±0.3 2.62±0.05 0.61±0.04 97±2.0 
F14 2.6±0.4 2.39±0.05 0.62±0.02 98±1.9 
F15 2.5±0.5 2.34±0.04 0.64±0.04 99±2.1 
mean±SD (n=3) 
 
Floating tablets of 15 different formulations of Risperidone were 
formulated by direct compression technique, using different 
polymers like HPMC K4, HPMC K15, HPMC K100, HPMC E15, 
Gelucire 50/13, Gelucire 44/14, WSR 301 and WSR N10. All the 
formulation was evaluated for their various physical parameters. 
The prepared 15 different formulations of Risperidone were 
evaluated for physicochemical properties and the results are 
depicted in table 2. The tablets were white, circular in shape and 
were found to be uniform with respect to weight variation (95 to 99 
mg) and hardness (2.3 to 2.7 kg/cm2). The thickness (2.34 to 2.62 
mm) and friability (0.52 to 0.75%) of different tablets were found 
within acceptable range.  
Fifteen formulations were evaluated for in vitro buoyancy lag time 
and total floating period and drug content. The time required for the 
tablet to rise to the surface (when the tablets were placed in a 
beaker containing 0.1 N HCl) for floating was described as the 
buoyancy lag time. NaHCO3 induces CO2 generation in the presence 
of HCl. All the formulations had buoyancy lag time in the range of 30 
to 84 sec. The total floating period was found to be more than 12 h, 
which indicates a stable gel layer formation by all polymers and that 
NaHCO3 remains for a longer time. Drug content uniformity in all 
formulations was calculated and the percent of active ingredient 
ranged from 72 to 99%. The results of floating lag time and total 
floating time was depicted in table 3. 
Study of swelling characteristics of risperidone floating tablets 
The percentage swelling obtained from the water uptake studies of 
formulations is shown in the table. The formulations with HPMC K4, 
HPMCK15 and HPMCK100, showed the swelling and tablet integrity. 
The change in sodium bicarbonate concentration did not show any 
effect on swelling of the tablet. The complete swelling was achieved 
at the end of 8hr, then diffusion and erosion take place. The 
formulation containing K100 shows the higher swelling compared to 
that of the formulations containing K15M and K 4M. The swelling 
index of the tablets increases with an increase in the polymer 
viscosity grade 
In vitro drug release studies 
All the formulations (F1-F15) were prepared with polymers like 
HPMC with different grades, POLYOX WSR 301and N10 and lipid 
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excipients Gelucire 44/14 and 50/13. The release of Risperidone 
from different formulations was carried out in 0.1N HCl and the 
results are depicted in Table. The highest drug release was found in 
the formulation F15 i.e. 99.45% within 12h when compared with 
other formulations. F15 was found to be optimized formulation 
based on the dissolution and other evaluation parameters. 
 
Table 3: In vitro floating ability and drug content of Risperidone floating tablets 
Formula code Buoyancy lag time* (sec) Total floating period* Drug content** (%) 
F1 84 >12 72±0.1 
F2 80 >12 85±0.1 
F3 77 >12 98±0.5 
F4 74 >12 83±0.2 
F5 70 >12 93±0.4 
F6 68 >12 78±0.2 
F7 65 >12 83±0.1 
F8 61 >12 96±0.3 
F9 57 >12 82±0.2 
F10 54 >12 91±0.1 
F11 50 >12 97±0.2 
F12 45 >12 95±0.5 
F13 40 >12 94±0.4 
F14 36 >12 87±0.2 
F15 30 >12 99±0.1 
mean±SD (n=3) 
 
Table 4: Cumulative %drug release of formulations F1-F5 
Time (h) F1 F2 F3 F4 F5 
0 0±0 0±0 0±0 0±0 0±0 
1 2.32±0.32 4.12±0.25 8.55±0.19 4.23±0.52 6.13±0.28 
2 9.43±0.28 16.87±0.12 23.65±0.28 12.64±0.85 18.54±0.29 
4 17.43±0.22 28.76±0.75 36.65±0.96 24.87±0.28 30.32±0.32 
6 26.54±0.96 43.67±0.96 52.43±0.25 34.65±0.29 46.43±0.42 
8 39.32±0.85 56.87±0.48 67.23±0.85 48.45±0.45 59.22±0.52 
10 56.23±0.45 73.22±0.48 84.54±0.55 6698±0.18 76.65±0.62 




Fig. 2: Drug release profiles of Risperidone formulations F1-F5 
 
Table 5: Cumulative percentage drug release of formulations F6-F10 
Time (h) F6 F7 F8 F9 F10 
0 0±0 0±0 0±0 0±0 0±0 
1 5.12±0.22 6.42±0.28 13.42±0.24 7.12±0.18 7.15±0.12 
2 10.25±0.52 21.44±0.62 22.44±0.52 16.32±0.22 22.11±0.32 
4 20.52±0.29 31.44±0.45 32.45±0.29 26.41±0.28 31.32±0.41 
6 32.88±0.63 44.42±0.28 47.75±0.62 38.75±0.85 47.18±0.44 
8 45.32±0.32 59.75±0.36 68.42±0.55 50.32±0.45 61.75±0.52 
10 59.58±0.52 73.52±0.98 81.75±0.75 66.42±0.28 75.62±0.66 
12 78.96±0.69 84.75±0.28 96.44±0.28 83.44±0.52 90.52±0.28 
mean±SD (n=3) 
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Fig. 3: Cumulative percentage drug release of formulations F6-F10 
 
Table 6: Cumulative percentage drug release of formulations F11-F15 
Time (h) F11 F12 F13 F14 F15 Innovator 
0 0±0 0±0 0±0 0±0 0±0 0±0 
1 8.32±0.85 9.36±0.62 10.58±0.32 10.75±0.75 11.18±0.42 96.85±0.52 
2 23.42±0.32 21.74±0.35 21.74±0.86 22.74±0.85 19.45±0.33 - 
4 32.45±0.52 30.85±0.95 32.65±0.28 42.75±0.75 31.74±0.32 - 
6 48.54±0.66 46.36±0.28 45.32±0.75 57.85±0.52 47.74±0.41 - 
8 64.85±.52 59.78±0.25 58.74±0.77 75.85±0.28 62.48±0.85 - 
10 78.74±0.75 75.48±0.85 78.39±0.96 92.58±0.74 81.77±0.18 - 




Fig. 4: Cumulative percentage drug release of formulations F11-F15 
 
Mathematical modeling of floating tablets 
To explore the mechanism of drug release from Risperidone floating 
tablets, various kinetic models like zero order, first order, Higuchi 
and Korsmeyer-Peppas equations were applied to the different 
formulations. The release order kinetics of Risperidone optimized 
formulation (F15) was shown in table 7. From the above results, it is 
apparent that the regression coefficient value closer to unity in the 
case of zero-order plot i.e. 0.983 indicates that the drug release 
follows a zero order mechanism. This data indicates a lesser amount 
of linearity when plotted by the first order equation. Hence it can be 
concluded that the major mechanism of drug release follows zero 
order kinetics. Further, the translation of the data from the 
dissolution studies suggested the possibility of understanding the 
mechanism of drug release by configuring the data into various 
mathematical modeling such as Higuchi and Korsmeyer-Peppas 
plots. The mass transfer with respect to the square root of time has 
been plotted, revealed a linear graph with regression value close to 
one i.e. 0.978 stating that the release from the matrix was through 
diffusion. Further, the n value obtained from the Korsmeyer-Peppas 
plots i.e. 0.905 suggest that the drug release from floating tablet was 
anomalous non-fickian diffusion. 
 
Table 7: Release kinetics of optimized formulation (F15) 
Formula code Zero order First order Higuchi Korsemeyer-Peppas 
F15 0.983 0.887 0.978 0.905 
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Drug-excipient compatibility studies 
FT-IR spectrum of Risperidone 
 
Fig. 5: FTIR spectrum of Risperidone pure drug 
  
 
Fig. 6: FT-IR spectrum of drug, HPMC K100 and WSR N10 
 
 
Fig. 7: FTIR spectrum of optimized formulation (F15) 
 
In order to get evidence on the possible interactions of the drug with 
excipients, FTIR analysis was used. The FTIR spectra of the 
optimized formulation displayed the characteristic peaks of both 
drug and polymers. Overall there was no alteration in the 
characteristic peaks of Risperidone suggesting that there was no 
interaction between the drug and polymer. 
 
Differential scanning calorimetry (DSC) 
 
Fig. 8: DSC thermogram of risperidone 
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Fig. 9: DSC Thermogram of HPMC K100 
 
 
Fig. 10: DSC Thermogram of WSR 301 
 
 
Fig. 11: DSC Thermogram of optimized formulation (F15) 
 
DSC was used to detect interactions between Risperidone and other 
excipients.  
The DSC thermogram of the pure Risperidone (fig. 8) and optimized 
formulation (F15) (fig. 11) showed endothermic peaks of the pure 
Risperidone and the Risperidone in the formulation at 170.94 and 
171.39 °C respectively. The endothermic peaks of the HPMC K100 
and WSR 301 were also shown in fig. 9 and 10 respectively. It 
indicates that there is no interaction takes place between drug and 
other excipients used in the formulation. 
Stability studies 
The stability of optimized formulation (F15) of Risperidone floating 
tablets were tested for stability at 40 °C/75%RH in properly closed 
HDPE bottles along with 1 gm desiccant for 3 mo. The Risperidone 
release rate (table 8) from the floating tablets (F15) showed no 
significant change during storage for 3 mo; there is no significant 
change in floating lag time, total floating time and also in vitro drug 
release profile. The formulation stored in both conditions for 3 mo 
floated on the surface of the media (0.1N HCl) for 12h. 
  
Table 8: Physico-chemical characteristics of optimized formulation (F15) stored at 40±2 °C/75±5%RH 
Retest time for F15 Floating lag time(sec)* Total floating time (h)* In vitro drug release profile (%)* 
0 d 30±2.6 >12h 99.45±0.12 
30 d 31±7.4 >12h 98.35±0.46 
60 d 31±1.2 >12h 97.61±0.52 
90 d 33±3.5 >12h 96.85±0.22 
*mean±SD (n=3) 
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Intragastric behavior of Risperidone floating tablets 
The radiographic images were taken at different periods post 
administration of the barium sulfate-loaded tablet in three human 
volunteers (fig. 12). It is clear that the tablet appears more or less at 
the same position for the initial 4h. This could be related to its 
floating ability. Later on, the tablet was slightly moved downwards, 
yet remained within the stomach till the end of 6 h. The increased 




Fig. 12: Radiographic images of optimized risperidone floating tablet (F15) in the stomach at different time intervals 
 
In vivo bioavailability studies 
 
 
Fig. 13: Plasma concentrations at different time intervals for Risperidone optimized formulation and marketed product 
 
Table 9: Comparison of pharmacokinetic parameters of Risperidone optimized formulation and marketed product 
Parameters Risperidone optimized formulation Marketed product 
Cmax(ng/ml) 4.35±73 5.10±33 
AUC0-t(ng. h/ml) 25.83±23.14 20.10±33 
AUC0-∞ (ng. h/ml) 28.42±18.24 23.80±18.12 
Tmax (h) 3.50±1.23 1.50±0.24 
t1/2 (h) 8.653±0.41 3.574±0.01 




Mean plasma concentration profiles of prepared Risperidone 
optimized formulation and marketed product are presented in fig. 
13. Risperidone optimized formulation exhibited as sustained 
release in vivo when compared with innovator tablet. All the 
pharmacokinetics parameters displayed in table 9. In this study in 
human subjects, prolonged drug absorption was achieved with the 
test formulation. The average peak concentration of the test 
formulation was significantly lower than that of the reference 
(4.35±73ng/ml for the test formulation versus 5.10±33ng/ml for the 
reference). In order to estimate the amount of drug absorbed from 
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the test formulation, the relative bioavailability was calculated from 
the AUC of the reference and test formulations (23.80±18.12ng. 
h/ml for the reference product versus 28.42±18.24ng. h/ml for the 
test formulation). The results indicated that the test formulation 
could increase the bioavailability of Risperidone in humans 
effectively. In this study, the Risperidone floating tablet produced 
higher bioavailability than that of a marketed product, this overall 
increase in bioavailability and increased gastric residence time, 
caused by flotation of the dosage form in the stomach. 
CONCLUSION 
An attempt was made to formulate and evaluate floating drug 
delivery system containing Risperidone as a model drug, from the 
data, obtained; it can be concluded that hydrodynamically balanced 
tablet of an antipsychotic drug Risperidone can be formulated as an 
approach to increase gastric residence time and thereby improve its 
bioavailability. Formulation F15 prolonged the release (99.45% up 
to 12 h) of the drug as compared to other prepared formulations. In 
vivo radiographic and bioavailability studies performed in healthy 
human volunteers. From radiographic studies, it is clear that the 
tablet remained within the stomach till the end of 6 h. Tmax, Cmax, AUC 
were calculated and confirmed significant improvement in 
bioavailability when compared with marketed formulation Respidon 
2. The data obtained thus suggests that floating delivery system can 
be successfully designed to give controlled drug delivery, improved 
oral bioavailability and many other desirable characteristics.  
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